Just watched Eli Lilly's earnings play out and it's honestly one of the wildest market swings I've seen in healthcare. The stock absolutely ripped on Feb 4 - up over 10% - then got absolutely hammered the next day. Classic market whiplash.

Here's what happened. Lilly crushed Q4 2025 expectations. Revenue hit $19.3 billion, blowing past the $17.9 billion consensus. EPS came in at $7.54, barely beating $7.48, but the real story was their 2026 guidance. They're projecting $81.5 billion in revenue and $34.25 adjusted EPS. That's 25% and 41% growth respectively. Analysts had been way more conservative - expecting 19% revenue growth and 36% EPS growth. So yeah, the market loved it.

But then Hims & Hers came in the next day and basically said they're undercutting everyone on oral semaglutide. They announced they'd sell copycat versions starting at $49 first month, $99 after. That's a hundred bucks cheaper than Novo, and significantly less than Lilly's planned $149-$399 pricing for their oral drug, orforglipron. Stock tanked 7.8% on that news.

What's interesting though - and this is where people might be overreacting - the actual compounded GLP-1 market is still tiny. UBS estimates around 1 million prescriptions for compounded versions versus 100 million for branded drugs from Novo and Lilly combined. So Hims is definitely a nuisance, but the idea that they can meaningfully block Lilly's growth? That seems overblown.

The real competitive dynamics are actually pretty clear when you look at the data. Lilly's injectable tirzepatide produces nearly 50% more weight loss than Novo's semaglutide. By end of 2025, Lilly had over 60% of the U.S. incretin market compared to Novo's 39%. A year prior they were basically tied. That's a massive shift and it reflects which drug doctors actually want to prescribe.

Now with orforglipron launching in Q2 2026, there's a whole new patient segment - people with needle phobia, patients looking to maintain weight loss after injectables. Even if Hims tries to undercut with generic versions, the branded drug has real advantages. The market's pricing in some caution right now, but updated analyst targets are averaging around $1,273, suggesting 25% upside from current levels.

Lilly's basically in the driver's seat here. Strong injectable demand, blockbuster oral drug incoming, and competitors struggling to keep pace. The Hims move is worth watching, but it doesn't change the fundamental picture. This is the kind of setup where the noise creates opportunities if you're paying attention.